A method is presented that uses combinatorial antibody libraries to endow cells with new binding energy landscapes for the purpose of regulating their phenotypes. Antibodies that are expressed in cells infected with a lentiviral combinatorial antibody library are selected directly for function rather than only for binding. The potential diversity space can be very large because more than one lentivirus can infect a single cell. Thus, the initial combinatorial diversity of ∼1.0 × 10 11 members generated by the random association of antibody heavy and light chains is greatly increased by the reassortment of the antibody Fv domains themselves inside cells. The power of the system is illustrated by its ability to select unusual antibodies. Here, the selected antibodies are potent erythropoietin agonists whose ontogeny depends on recombination at the protein level of pairs of antibodies expressed in the same cell to generate heterodimeric bispecific antibodies. The obligate synergy between the different binding specificities of the antibody's monomeric subunits appears to replicate the asymmetric binding mechanism of authentic erythropoietin.
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agonist antibodies | phenotypic perturbation | erythropoietin phenocopy A ntibodies are currently an important therapeutic option for treatment of a wide variety of diseases (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The field of immunochemistry has now turned its attention to more challenging goals, such as the generation of broadly neutralizing antiviral antibodies where a useful molecule may be very rare. This frequency problem has been largely solved by the advent of combinatorial antibody libraries where today one can select from a repertoire that contains as many as 10 11 different members (12) . The power of this approach has been demonstrated in the study of influenza viruses where the selection of rare antibodies has led to the discovery of new modes of virus neutralization, thereby offering previously unrealized possibilities for therapy and even the generation of a universal vaccine (13) .
However, even with a solution to the frequency problem, isolation of an antibody whose function goes beyond simple binding is still a less-than-perfect two-step process where one first screens for binding and then function. To generate agonist antibodies, the difficulty is compounded by the fact that the secondary screen for function can only be carried out in eukaryotic cellular systems where antigen presentation may be constrained by the milieu or by the concentration of the target protein, compared with screening in vitro against highly purified molecules. Thus, for agonists, the power of a process that begins as a selection from a vast diversity of antibodies expressed in either yeast or phage, for example, is dampened by the bottleneck of the secondary screen where one essentially studies each antibody individually. Paradoxically, the complexity of the secondary screen is proportional to the success of the first screen, which in phage systems can yield thousands of candidate antibodies.
Here, we present a unique method that allows one to select directly for functional antibodies in eukaryotic cells. To accomplish this selection, we constructed a combinatorial antibody library in lentiviruses where, after infection, antibodies are efficiently expressed inside cells and also secreted such that both intracellular and extracellular targets can be accessed. One important feature of the method derives from the fact that, in the lentivirus system, more than one virus can infect a single cell. This situation would be a disadvantage if one wished to study the effect of a single protein, but for a diversity system such as antibodies, this multiplicity of infection allows study of the combinatorial synergy of multiple proteins at once in a format that can be easily deconvoluted. Thus, though combinatorial antibody libraries in phage can contain 1.0 × 10 11 members, at present a workable library in lentivirus starts with only ∼1.0 × 10 7 members. However, given the potential of multiple different viruses per cell, the further combinatorial associations at the protein level greatly increase the potential intracellular diversity of the library. To challenge this unique method, we attempted to select directly for antibodies that are phenocopies of erythropoietin (EPO). Remarkably, we selected a mechanistically unique antibody whose agonist function depends on the obligate synergy between two different antigen-binding specificities that must be contained within the same antibody molecule. This asymmetric binding of the heterodimeric antibody replicates the mechanism of authentic EPO whose full agonist activity depends on activation of the JAK2/Stat5 pathway by its asymmetric binding to two nearly identical sites on the EPO receptor (EpoR) monomers (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) .
Results

Isolation of EpoR Binding Antibodies from a Combinatorial Library.
The initial goal of our method was to express as large an antibody library as possible inside eukaryotic cells where the antibodies can be either contained in the cytoplasm or secreted. To accomplish this in a way that gives the greatest degree of freedom, we used both M-13 phage and lentivirus vectors that were constructed so that the antibody genes could be easily interchanged (Fig. S1) . A naïve human combinatorial antibody library based on antibody genes from 60 different samples of human peripheral blood lymphocytes (PBLs) was used. The library diversity is 4.5 × 10 9 (27) . In general, there are two approaches to the problem of selecting antibodies that regulate phenotypes; which to use depends on whether the target is known. We could use either conventional panning of a combinatorial antibody library in phage to enrich for antibodies against the target proteins and then switch the selected genes into lentiviruses, or we could use the lentivirus library directly without prior selection (Fig. 1) . Initial selection in phage is optimal when the target is known, because phage systems can interrogate a much larger diversity space (∼1.0 × 10 11 ) than is possible in eukaryotic systems. However, when little is known about the molecular components of a pathway, direct phenotypic selection in eukaryotic cells is the preferred option. In the experiment reported here, one already knew that the EpoR is the target of EPO, and thus we first selected antibodies that bound to the EpoR from combinatorial libraries in phage. Because it may be critical to select antibodies to the correct configuration of the EpoR, only panning in solution was attempted. The target proteins were an EpoR dimer constructed as an Fc fusion or His-tagged monomeric EpoR. Two different protocols were used (Fig. S2 ). The first protocol (P1) was designed to address epitopes that were not directly competitive with the EPO binding site but were still accessible in the dimer. The first two panning rounds alternated between the EpoR dimer-Fc fusion and the His-tagged monomeric EpoR. These rounds were followed by a third round that used the monomeric EpoR to eliminate any residual phage that targeted the Fc region of the construct. Glycine·HCl (pH 2.2) was used to elute bound phage. Thus, in the first round, all antibodies that bound to the EpoR dimer Fc fusion protein were selected, and in the second round, the pool was narrowed to eliminate antibodies whose reactivity was dependent on the Fc fusion partner. In the second protocol (P2), phage attached to the EpoR dimer Fc fusion were collected on protein G beads, after which specific elution with EPO was carried out. This protocol was used to enrich for antibodies that bound at or near the EPO binding site of the EpoR. The enrichment parameters for each round of the phage panning experiments are given in Table S1 . To sample the results of the panning, 48 clones from each protocol were randomly picked for phage ELISA using adsorbed His-tagged monomeric EpoR as the antigen. About half of the clones from each procedure bound specifically to the EpoR relative to nonspecific binding to BSA. There was a spectrum of reactivity as determined by phage ELISA (Fig. S3A ). Sequence analysis of the reactive clones showed that they could be arranged into 21 different families (Fig. S3B) . In some cases, the same antibodies were selected using both protocols, whereas in others the selected antibodies were from only one protocol (P1 vs. P2; Fig. S3B ).
Selection of Agonist Antibodies. The genes encoding the antibodies that bound to the EpoR that were selected in phage by each protocol were transferred separately to lentiviruses, which were used to infect TF-1 cells that we had engineered to overexpress WT EpoR. Expression of WT EpoR in TF-1 cells is a necessary complement to their endogenous truncated EpoR for sustained cell growth (28) . To facilitate study of the expression of the EpoR, WT EpoR and GFP were linked with a T2A linker (Fig. S1 ). The expression of antibodies in the cells infected with lentiviruses, using either the EF1α or the UbC promoter, was analyzed by Western blot analysis ( Fig. 2A) . The amount of antibody expressed was higher with the EF1α promoter ( Fig. 2A) .
To determine if any expressed antibodies could substitute for EPO, infected and control cells were plated in EPO-free soft agar and observed after 14 d for growth of red colonies (Fig. 2B) . Only the cells infected with viruses that encoded antibodies yielded red colonies (Fig. 2B) . The fact that a control vector that only encoded GFP did not induce growth of any colonies showed that the observed colony growth was not the result of insertional mutagenesis induced by integration of the lentiviral genome. Whereas authentic EPO induced growth in most of the plated cells, growth of cells containing only antibody genes was much Fig. 1 . Scheme for selection of antibody agonists from combinatorial libraries. Antibodies that bound EpoR were selected from a combinatorial antibody library displayed in phage by affinity-based selection. The antibody genes from the selected phage were cloned into lentiviral vectors to allow phenotypic selections after infection of eukaryotic cells and integration of the antibody genes into the genome. The transduced cells were plated in methylcellulose agar such that the secreted antibodies were trapped around the cells producing them. The colonies that formed were harvested using a micromanipulator, and the antibody genes were recovered by PCR. The PCR products were cloned and sequenced, and the respective antibodies or antibody combinations were tested for their activity. The active antibodies were expressed in mammalian cells and purified for further characterization. Colonies are shown where either bright-field microscopy to study the morphology and the color of the colonies or fluorescence microscopy to monitor the expression of the EpoR were used. TF-1 cells transduced with the EPO gene were used as positive controls. The colonies whose growth was independent of EPO were harvested with a micromanipulator. To produce antibodies, single antibody genes from the selected cell colonies were transfected into HEK293T cells.
less frequent even though more than 80% of cells were infected (Fig. S4) . Thirty-three colonies from infected cells were picked and the antibody genes were recovered by PCR and cloned into the lentiviral vector (Fig. S1 ). The genes encoding the antibody CDR3 regions were analyzed to determine the number of different sequences in a given clone (Dataset S1). This analysis showed that between one and four different lentiviruses were recovered from each colony (Dataset S1). Because the initial sequencing of the antibody genes isolated from phage that bound to the EpoR was only a sampling of the available diversity, some different sequences were found in the clones that were selected by lentivirus infection (Dataset S1). Importantly, some sequences appeared multiple times in different selected clones (Dataset S1).
EPO Activity of the Selected Antibodies. The antibodies encoded by the lentiviruses were produced by transient transfection of HEK-293T cells and tested for their ability to induce proliferation of TF1 cells. Because these antibodies were presumably selected for their agonist activities, we were not surprised to find that two of them showed modest to moderate activity compared with authentic EPO (Fig. 3A) . These antibodies (E-3 and Z-1) had only ∼60% of the activity of authentic EPO (Fig. 3A) ; however, even though they originated from different colonies that were harvested on different days, sequence analysis showed that they were, in fact, the same antibody.
Obligate Bispecificity. Because many clones expressed more than one antibody, there was the possibility that the observed agonist Fig. 3 . Antibody synergy from transfections. (A) The ability of the individual antibodies to induce TF-1 cell proliferation was tested using the conditioned medium from HEK293T cells 48 h posttransfection of individual antibodies. The TF-1 cells were mixed with an equal volume of conditioned medium in microtiter wells and cultured in the absence of EPO for 72 h. The number of viable cells was determined by an MTS assay. Antibody E-3 was the strongest agonist, with ∼60% of the activity of authentic EPO. (B) To study synergy, all combinations of two antibody genes isolated from the same colonies were transfected into HEK293T cells. TF-1 cell proliferation was tested using conditioned medium obtained 48 h posttransfection. The TF-1 cells were mixed with an equal volume of conditioned medium and cultured without EPO for 72 h. The number of viable cells was determined by an MTS assay. Cotransfection with the V-1/V-2 genes gave the strongest activity that was equal to that of EPO. All unique antibody sequences and the combination of all possible antibody pairs from each colony (A-AG) were tested. Some antibodies with the same sequences were recovered from different colonies and are, thus, repeated in the graph. Approximately the same amount of antibody as determined by Western blot was used for each study.
activity was dependent on the synergy between different antibody specificities. To test this idea, antibodies from conditioned media produced in HEK-293T cells were observed for their ability to induce cell proliferation in a MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. For example, for colonies that had antibody sequences A, B, and C, the cotransfected pairs included sequences AB, AC, and BC. A total of 49 combinations were tested (Fig. 3B) . Some of these combinations gave markedly enhanced agonist activity that in one case (V-1/V-2) was as strong as authentic EPO (Fig.  3B) . Importantly, when V-1 is paired with other antibodies such as D-1, K-1, O-1, O-3, and AA-1, all activity was lost.
There are two possible routes to these synergistic effects. In one scenario, two different homodimeric antibody molecules could simply be additive. However, because of the format used here where the scFvs are fused to the Fc fragment of the Ig molecule, there is the alternate possibility that heterodimers will be formed in a cell that expresses more than one antibody.
To determine the molecularity of the observed synergy, we studied whether the two different binding specificities had to be present in the same Ig molecule. To purify the possible antibody combinations, cells were transfected with an expression vector encoding either a homodimeric antibody or a heterodimer whose partners were dictated by "knobs-into-hole" engineering of the Fc fragment (29) . Fortunately, the potential antibody partners had slightly different sizes so that the purity of the knobs-into-hole construct after protein G chromatography could be confirmed by acrylamide gel analysis (Fig. 4) . Although all of the purified antibodies bound to the EpoR (Fig. 4B) , neither the individual antibodies nor simple mixtures of two different antibodies had any agonist effect (Fig. 4C) . However, when the two specificities were combined in a single antibody molecule, the protein had strong EPO-like activity equivalent to that seen when multiple antibody species were generated inside cells by cotransfection (Fig. 4C) . The maximum response of the bispecific heterodimeric antibody and EPO were similar (Fig. 4C) . Importantly, the heterodimeric bispecific antibody (V-1/V-2) was a full agonist, unlike any of the homodimeric antibodies, notwithstanding the fact that one of the homodimeric antibodies did show a maximum agonist effect of ∼60% (Figs. 3A and 4C ). The EC 50 for the BsAb is 1 nM compared with EPO, which is 0.1 nM. The specificity of the agonist effect was confirmed by showing that it could be completely inhibited by the purified EpoR ectodomain (Fig. 4D) . Furthermore, the binding specificity of the anti-EpoR antibodies was confirmed by showing that they did not react with other proteins, including the thrombopoietin receptor.
To confirm the agonist activity of the various antibody constructs, their ability to induce hemoglobin synthesis and protein phosphorylation was studied in TF-1 and TF-1 WT EpoR cells (Fig. 5 A and B) . The heterodimeric bispecific antibody induced hemoglobin synthesis (Fig. 5A ) and much greater phosphorylation of JAK2 and Stat5 than either EPO or GM-CSF themselves (Fig. 5B) . Because GM-CSF is required for maintenance of TF-1 cells, its effects on phosphorylation of JAK2 and Stat5 were also studied as an additional positive control (Fig. 5B) .
Asymmetric Cooperativity. A biolayer interferometry analysis of the binding parameters of the component antibodies showed that each bound to the EpoR where V1 had an affinity of 47 nM compared with 138 nM for V-2 (Fig. S5) . Authentic EPO competed with antibody V-2, but not V1, for binding to the EpoR (Fig. S6A) , demonstrating that only one of the antibodies bound in the vicinity of the EPO binding site, and the other bound elsewhere. Thus, both EPO and the bispecific antibody achieve the obligatory asymmetric binding to the EpoR that is necessary for full agonist activity, albeit in different ways. In the case of EPO, asymmetry is achieved by the use of two distinct interfaces (site 1 and site 2) that each bind with different affinities to essentially a single site in the homodimeric EpoR (14, 15, 22, 23, 25, 26) By contrast, the heterodimeric bispecific antibody achieves asymmetry by using its two different binding specificities to interact with different sites on the EpoR (Fig. 6) . Thus, the binding stoichiometry changes from 1:2 to 2:2.
To determine the nature of the binding cooperativity between the two different specificities, a competition experiment was designed that allowed study of the effect that each antibody had on the binding of the other to an EpoR monomer. Thus, competition between an unlabeled scFv-Flag fusion and a biotinylated scFv-Flag fusion could be monitored with HRP-labeled streptavidin to measure the effect of the binding of one antibody on the off-rate of the other. As expected, the homodimeric antibodies with the same specificity in each arm of the dimer compete with Fig. 4 . Synergy in antibody protein constructs. The single antibodies V-1 and V-2 and the BsAb V-1/V-2 that were generated using knobs-into-hole technology were purified from HEK293F cells. (A) The purified proteins were analyzed using 7% Tris-acetate gels with Tris-acetate running buffer. (B) Antibody binding to the EpoR was tested by a pull-down experiment. Different antibodies were mixed with the extracellular domain of hEpoR His-tag. The complexes were captured with His-tag Dynabeads, and bound antibodies were detected with an anti-Fc: HRP antibody. (C) The dose-response curve for the abilities of the heterodimeric BsAb and the homodimeric antibody E-3, the most potent single antibody (Fig. 3A) to stimulate the proliferation of the EPO-dependent TF-1 human erythroleukemic cells. The maximum response of the BsAb is equal to EPO showing that it is a full agonist, whereas the strongest homodimeric antibody E-3 showed only 60% of the maximum response generated by authentic EPO. (D) To show that the purified EpoR ectodomain Fc chimera inhibits the antibody agonist activity, TF-1 cells were treated with antibodies or untreated (Ctrl) at a concentration of 10 nM in the presence of increased concentrations of the EpoR ectodomain Fc fusion protein.
each other (Fig. S6B ). This finding is in striking contrast to the results for the homodimeric pairs with different specificities that did not compete with each other (Fig. S6B) , again confirming that they bound to different regions of the EpoR. This result also indicates that the two different antibodies were not allosteric partners.
Induction of Human Bone Marrow Stem Cells. The TF-1 cells that we studied here are widely used to assay for activities of a variety of cytokines (30) ; as a cell line, however, they might not be faithful representatives of the actual red cell progenitors in the bone marrow. Thus, we wanted to demonstrate that our agonist antibodies induced erythropoiesis from human bone marrow hematopoietic stem cells. The bispecific agonist antibodies were used to stimulate CD34+ stem cells that were freshly isolated from human bone marrow. After 1 wk, cell proliferation and hemoglobin synthesis were already evident (Fig. 5C) . To put the results on a more quantitative basis, the number of induced colonies was counted after 14 d. Authentic EPO and the bispecific antibody induced approximately the same number of colonies (Table S2) .
Discussion
The central objective of the present work was to develop a method for the generation of unique binding energy landscapes within a population of cells for the purpose of selecting phenocopies of physiological events. Though others have studied the intracellular expression of single antibodies to a known target (31-33), our approach is very different in that we can study the consequences of the expression of massive numbers of proteins, each with different binding specificities, inside a population of cells.
The ability to select directly synergistic antibodies from cells expressing more than one antibody offers a second combinatorial degree of freedom that operates at the level of whole scFv antibodies and can add to the diversities already achieved by the random association of very large numbers of antibody heavy and light chains. Thus, the first combinatorial parameter is the random association of heavy and light chains of the antibody molecule to give large numbers of monospecific homodimers. Because the association of the scFv-Fc fusions is degenerate, the second combinatorial parameter derives from the random reassortment of the multiple binding domains (scFvs) of the antibody molecules themselves to give bispecific heterodimers. Here, the term "bispecificity" refers to the ability of the heterodimer to bind to two different sites within the same molecule (cis reactivity), which differs from the way the term is usually used in immunochemistry where it refers to the potential to bind to two different molecules (transreactivity). In general, we expect the system will reveal a myriad of effects as a consequence of the perturbation of cellular phenotypes by expression of unique protein binding energies inside cells. From an evolutionary point of view, those antibodies that exactly copy physiological mechanisms are of interest. Arguably, however, the most interesting cases will be those antibodies that reveal kinetically possible but otherwise unused manifolds, as was likely observed here. Finally, because the viruses in the library are vesicular stomatitis virus/lentivirus pseudotypes, they have a broad host range and, thus, can be used in a wide variety of cells.
Our method differs from that of others who also attempted to generate antibody agonists, not only in the nature of the unique bispecific molecules that it yielded, but also because its power derives from selection rather than screening. For example, both Liu et al. (34) and Lim et al. (35) had to screen several thousand antibodies from antibody libraries that bound to the EpoR to find agonists. Even so, because the antibodies were homo- In the model, potent agonist activity is likely to be associated with asymmetric binding of the heterodimeric bispecific antibodies as for EPO (14, 15) . Asymmetric binding reorients the D1 and D2 ectodomains for optimal signaling via the JAK2/Stat5 pathway. One homodimeric antibody is only a partial agonist, which suggests a more symmetric interaction with less activation as for a peptide agonist (16) . Antibodies that bind EpoR, but do not activate, likely bind to only one arm of the EpoR unliganded dimer (17) (18) (19) in an orientation that precludes bivalent association of the antibody. dimers, they could not replicate the mechanism of authentic EPO that requires asymmetric binding and, as seen here for homodimeric molecules, their best antibody from the screening had only about 60% of the activity of authentic EPO. The advantage of selection is that it can lead directly to a ligand that is molecularly balanced for an effect in a way that currently may be difficult to achieve by screening only for binding or by design. For instance, if we take at face value what we have already learned about the EPO antibody that has full agonist activity, it appears to require cooperativity of two different binding specificities whose agonist mechanism is similar to the asymmetric interaction of EPO with the EpoR (14) . Thus, the fact that antibodies with either specificity can bind to EpoR, but only act as potent agonists when they are combined in the same molecule, suggests that simple dimerization of the EpoR is not sufficient for activity, or their dimer configurations are more similar to partial agonists (16), antagonists (19) , or unliganded dimers (17, 18) (Fig. 6) . However, because the antibody is bispecific, we cannot rule out the possibility that they generate higher order forms of the EpoR that contribute to the agonist activity.
The ability to observe a phenotype in our system may only be limited by the ability to construct cellular reporting systems. As illustrated here, one powerful format uses positive selection because it lends itself to easy recovery of the functioning antibodies. However, a slight change in the format should allow for negative selection of events, such as cell death, that could be important for finding new targets for cancer therapy. Here, one can use cocultivations of differentially labeled feeder cells that produce the antibodies and target cells followed by selection for colonies or plaques where only feeder cells are present because the target cells have been killed. As for gene ablation and RNAi methods, one may use libraries that are not preselected on any target to isolate antibody agonists that act indirectly by perturbation of regulatory molecules. This method may be particularly important for the study of antibodies that regulate the differentiation of stem cells, identification of tumor suppressor gene products, or for generation of agonists that are currently missing from the therapeutic armamentarium, such as, for example, a thrombopoietin phenocopy. Finally, the method may be important to identify new therapeutic targets, even when they are not addressable by antibodies. Thus, when molecules that are exclusively intracellular are identified, they may be novel targets for smallmolecule therapeutics, which could be especially important in cancer, where targets may be exclusive to certain types of cancer or even tumors isolated from individual patients.
Though we choose the EPO signaling system simply to illustrate the potential of the method to select directly agonist phenocopies, some of the selected antibodies turned out to be mechanistically interesting in their own right and may portend a unique class of immunochemical reagents. Thus, the system was powerful enough to select for potent bispecific heterodimeric EPO-agonist antibodies that appear to replicate the complicated asymmetric binding mechanism used in the natural cytokine receptor signaling pathway (22) (Fig. 6 ).
Materials and Methods
The methods of panning combinatorial antibody library against EpoR protein, construction of lentiviral antibody library, package of lentiviral library, transduction of TF-1 cells, and selection of cell colonies in soft agar assay are detailed in SI Material and Methods. The recovery of antibody genes from colonies was established by PCR amplification. Antibody expression, purification, and biochemical characterization of antibodies are detailed in SI Materials and Methods. The cell proliferation assay, analysis of protein phosphorylation in signaling pathway, and hematopoietic stem cell colony forming assay are detailed in SI Materials and Methods.
